Marketers will need to address not only the benefits of the therapy but also the benefits of a diagnostic assay.
Kathleen Dunn, KFDunn Life Sciences
Advertisement
Articles by Kathleen Dunn, KFDunn Life Sciences
Advertisement
Latest Updated Articles
Personalized Medicines: Implications for PharmaPublished: December 1st 2009 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
2
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
3
Direct-to-patient: pharma’s next power move
4
AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski
5
